AI assistant
CSL Ltd. — Regulatory Filings 2007
Nov 28, 2007
17854_rns_2007-11-28_d6e74d71-28d7-4437-973f-1cbdba9d3af8.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [88 x 111] intentionally omitted <==
Arana Therapeutics Completes Project With CSL
Thursday, 29 November 2007 Sydney, Australia : Biotechnology company, Arana Therapeutics Limited (ASX: AAH, AIM: AAHx) today reported that it has successfully completed a collaborative project with its pharmaceutical partner CSL Limited (CSL).
Provision of the final report triggers a further payment to Arana from CSL under the terms of the collaboration agreement between the two companies.
Under the agreement, signed in June 2006 and extended to cover additional work in December 2006, Arana utilised its Superhumanisation[TM] technology to develop humanised versions of lead antibodies from the CSL pharmaceutical pipeline. These humanised products have then been affinity matured using Arana’s EvoGene[TM] optimisation technology. Should CSL choose to develop one of these antibodies through clinical testing, Arana will be eligible to receive milestone payments and will earn royalty payments on the sale of all marketed products.
Arana is employing its technology platform to develop valuable protein therapeutics both internally, as well as in further collaborations with international pharmaceutical giant GSK and Melbourne-based Vegenics Limited. Arana has also more recently announced an alliance with US-based Aveo Pharmaceuticals to use Arana’s Superhumanisation[TM] technology for the internal development of several Aveo products.
Arana CEO, Dr John Chiplin, said: “The completion of the project with CSL continues to deliver on the success of the technology partnerships that the company has very successfully built upon over the last 2 years.”
“In March 2007 Arana announced successful validation of its first project with GSK with a follow up announcement confirming commencement of a second project with GSK, again on a lead product from the GSK pipeline.”
“We are of course delighted that we have once again succeeded in delivering to our partners a quality product with improved properties suitable for direct use as a therapeutic”, he added.
Arana Therapeutics Limited 19-25 Khartoum Road Macquarie Park Sydney NSW 2113 Australia P +61 2 9870 8788 F +61 2 9870 8786 ABN 98 002 951 877
==> picture [549 x 33] intentionally omitted <==
About Arana Therapeutics:
Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical company formed through the merger of Peptech and EvoGenix in August 2007. The company uses superior technology to develop next generation drugs that will improve the lives of patients with inflammatory diseases and cancer.
Arana Therapeutics’ innovative engineering technologies provide the basis for clinical development in the antibody space, a market which draws on high demand. With a market capitalisation of around A$250 million and solid cash resources, Arana Therapeutics has the financial stability and management expertise to accelerate its clinical programs, and is on track to have at least 3 clinical stage assets within three years.
Arana is listed on the Australian Securities Exchange (ASX) and the London Stock Exchange (AIM).
The lead pipeline consists of four lead drug programs: ART621 to treat severe rheumatoid arthritis and other inflammatory diseases; ART010 to treat osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal cancer; and ART150 for lung cancer and melanoma. Additionally the company has earlier stage products in development for the treatment of a range of conditions including age related macular degeneration, psoriasis, colorectal cancer, and leukaemia.
The most advanced drug candidate ART621 will commence Phase II clinical trials in 2008. In development for the treatment of severe rheumatoid arthritis, and other inflammatory disorders, ART621 has been shown to be well-tolerated in healthy volunteers at a variety of dose levels when administered intravenously or under the skin.
Arana has recurring revenues from commercial and development partnerships with six international companies including GSK, CSL, Centocor (J&J) and Abbott Laboratories.
For further information: www.arana.com
Contact information: Company: Dr John Chiplin Chief Executive Officer Arana Therapeutics Limited T: + 61 2 9870 8788 E: [email protected]
Investor & Media Relations:
Rebecca Wilson Buchan Consulting T: + 61 2 9237 2800 Mobile: 0417 382 391 E: [email protected]
==> picture [549 x 33] intentionally omitted <==